AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33784898 — intervention group
Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 242
Study 34426648 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss dietary intervention
Number of subjects: 395
Study 33231036 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulating mate availability
Number of subjects: 1950
Study 33231036 — intervention group
Group type: COMPARATOR
Intervention: Manipulating pathogen threat
Number of subjects: 1950
Study 34775948 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified high-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 788
Study 34775948 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 788
Study 34750724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) via a mask, mean SpO2 of 85%, 70 min of hypoxia
Number of subjects: 10
Study 34750724 — intervention group
Group type: COMPARATOR
Intervention: Sham-intermittent hypoxia (Sham-IH) control
Number of subjects: 10
Study 34750724 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hypoxia (CH) via a mask, mean SpO2 of 85%, 70 min of hypoxia
Number of subjects: 10
Study 34750724 — intervention group
Group type: COMPARATOR
Intervention: Sham-control for continuous hypoxia (Sham-CH)
Number of subjects: 10
Study 32034697 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endostatin levels (≥ 84.22 ng/mL)
Number of subjects: 613
Study 32034697 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endostatin levels (highest vs lowest quartile)
Number of subjects: 613
Study 32034697 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding endostatin to a model containing conventional factors
Number of subjects: 613
Study 34847750 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAIL GalleriTM multi-cancer screening test (screening)
Number of subjects: 140000
Study 34847750 — intervention group
Group type: COMPARATOR
Intervention: Unexposed (no screening)
Number of subjects: 140000
Study 32955200 — intervention group
Group type: EXPERIMENTAL
Intervention: AXA1665 14.7 g t.i.d.
Number of subjects: 40
Study 32955200 — intervention group
Group type: COMPARATOR
Intervention: Control t.i.d.
Number of subjects: 40
Study 35022179 — intervention group
Group type: EXPERIMENTAL
Intervention: MindOnLine programme (n=200)
Number of subjects: 400
Study 35022179 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=200)
Number of subjects: 400
Study 35790435 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed helical CT projection data restoration model
Number of subjects: 0
Study 35790435 — intervention group
Group type: COMPARATOR
Intervention: IRLNet, REDCNN, MWResNet
Number of subjects: 0
Study 32994381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic aquatic training
Number of subjects: 3
Study 32994381 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aquatic training
Number of subjects: 3
Study 32994381 — intervention group
Group type: COMPARATOR
Intervention: Procedure control
Number of subjects: 3
Study 36369133 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and intradermal press needles (Acupuncture group, n=35)
Number of subjects: 64
Study 36369133 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 64
Study 33515536 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS targeting the dACC
Number of subjects: 23
Study 33515536 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 23
Study 32216457 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 30
Study 32216457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34670131 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP-NX), n = 287
Number of subjects: 570
Study 34670131 — intervention group
Group type: COMPARATOR
Intervention: Extended-release naltrexone injection (XR-NTX), n = 283
Number of subjects: 570
Study 32350694 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient group (angle α = 38.56°)
Number of subjects: 671
Study 32350694 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched, angle α = 48.48°)
Number of subjects: 671
Study 35351180 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Bolus
Number of subjects: 72
Study 35351180 — intervention group
Group type: COMPARATOR
Intervention: Normal Bolus
Number of subjects: 72
Study 33734145 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (n = 1100)
Number of subjects: 2111
Study 33734145 — intervention group
Group type: COMPARATOR
Intervention: Confirmatory factor analysis (n = 1011)
Number of subjects: 2111
Study 33734145 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological Pain Measures
Number of subjects: 2111
Study 33734145 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Pain Measures
Number of subjects: 2111
Study 32824408 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR)
Number of subjects: 8
Study 32824408 — intervention group
Group type: COMPARATOR
Intervention: Whole Food (WF)
Number of subjects: 8
Study 35225510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal antifungal agents and systemic therapy
Number of subjects: 0
Study 35225510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0
Study 35225510 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer molecular microbiological technologies
Number of subjects: 0
Study 35225510 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal stewardship
Number of subjects: 0
Study 32460239 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate-flavored dairy milk recovery beverage (1.2 g/kg body mass carbohydrate and 0.4 g/kg body mass protein)
Number of subjects: 11
Study 32460239 — intervention group
Group type: COMPARATOR
Intervention: Water volume equivalent
Number of subjects: 11
Study 35168142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg/day
Number of subjects: 0
Study 35168142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg/day
Number of subjects: 0
Study 35168142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg/day and 400 mg/day with SCBs
Number of subjects: 0
Study 35168142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate with non-SCB ASMs
Number of subjects: 0
Study 35168142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33788024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose purified EPA (icosapent ethyl)
Number of subjects: 0
Study 33788024 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (statins)
Number of subjects: 0
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy diet
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported feeling sad
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: History of periods of stress
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent stress
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2047
Study 32770968 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease (CHD)
Number of subjects: 2047
Study 32770968 — intervention group
Group type: COMPARATOR
Intervention: Comparison of men vs women
Number of subjects: 2047
Study 32770968 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urban vs rural areas
Number of subjects: 2047
Study 32770968 — intervention group
Group type: COMPARATOR
Intervention: Comparison of younger vs older participants
Number of subjects: 2047
Study 33734167 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070 3.8 mg/24 hours
Number of subjects: 0
Study 33734167 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070 7.6 mg/24 hours
Number of subjects: 0
Study 33734167 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070 (daily application)
Number of subjects: 0
Study 33734167 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070 with external heat
Number of subjects: 0
Study 33734167 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-3070
Number of subjects: 0
Study 32530717 — intervention group
Group type: COMPARATOR
Intervention: Group seated rest in a relaxing environment (SR)
Number of subjects: 11
Study 32530717 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based physical therapy (YPT)
Number of subjects: 11
Study 32530717 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy (CPT)
Number of subjects: 11
Study 32989470 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous injection) plus calcitriol (0.5 μg/day) and calcium carbonate (1000 mg/day)
Number of subjects: 95
Study 32989470 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcitriol 0.5 μg/day and calcium carbonate 1000 mg/day without ZOL)
Number of subjects: 95
Study 32446280 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) intervention
Number of subjects: 205
Study 35642923 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral vitamin B12 (1000 µg IM for initial dose, followed by 3 doses on alternate days for <10 years or 5 doses for >10 years, then monthly 1000 µg IM)
Number of subjects: 80
Study 35642923 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin B12 (1500 µg daily for 3 months, 500 µg for <2 years)
Number of subjects: 80
Study 35274362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot intervention based on the StudentBodies© program
Number of subjects: 700
Study 35274362 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 700
Study 34047303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 2939
Study 34047303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2939
Study 32388179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 1945
Study 32388179 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 1945
Study 34931904 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking meditation
Number of subjects: 68
Study 34931904 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 68
Study 34277328 — intervention group
Group type: EXPERIMENTAL
Intervention: Public healthcare sector claims
Number of subjects: 274
Study 34277328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual communicators
Number of subjects: 274
Study 34277328 — intervention group
Group type: EXPERIMENTAL
Intervention: Laypeople communicators
Number of subjects: 274
Study 34277328 — intervention group
Group type: COMPARATOR
Intervention: Private healthcare sector claims
Number of subjects: 274
Study 34277328 — intervention group
Group type: COMPARATOR
Intervention: Collective communicators
Number of subjects: 274
Study 34277328 — intervention group
Group type: COMPARATOR
Intervention: Expert communicators
Number of subjects: 274
Study 33447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration with clindamycin for one week postoperatively
Number of subjects: 98
Study 33447866 — intervention group
Group type: COMPARATOR
Intervention: Incision drainage
Number of subjects: 98
Study 33447866 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 98
Study 32430771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopharyngeal packing (HP) during adenotonsillectomy
Number of subjects: 129
Study 32430771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypopharyngeal packing)
Number of subjects: 129
Study 32430771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopharyngeal packing (HP)
Number of subjects: 129
Study 36364801 — intervention group
Group type: EXPERIMENTAL
Intervention: WPH (ERD + 20 g/d WPH)
Number of subjects: 60
Study 36364801 — intervention group
Group type: COMPARATOR
Intervention: Control (ERD)
Number of subjects: 60
Study 36364801 — intervention group
Group type: EXPERIMENTAL
Intervention: WP (ERD + 20 g/d WP)
Number of subjects: 60
Study 33301158 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (required to walk more than 12,000 steps within 6 hours after HSG)
Number of subjects: 100
Study 33301158 — intervention group
Group type: COMPARATOR
Intervention: Control group (prohibited from performing high‐intensity exercise)
Number of subjects: 100
Study 34556273 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN XT TAVR
Number of subjects: 1524
Study 34556273 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 TAVR
Number of subjects: 1524
Study 34556273 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1524
Study 33412544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu Bronchosampler with aScope 4
Number of subjects: 20
Study 33588527 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat (JNJ-54861911)
Number of subjects: 0
Study 33970205 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management after the index stroke (93% of patients with CW)
Number of subjects: 30
Study 33970205 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (EVT)
Number of subjects: 30
Study 32012319 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 52
Study 32012319 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Number of subjects: 52
Study 32012319 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Mirror Feedback (VMF)
Number of subjects: 52
Study 32012319 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 52
Study 35431038 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP with recruitment manoeuvres
Number of subjects: 3837
Study 35431038 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 3837
Study 32761372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once a day (GA100)
Number of subjects: 59
Study 32761372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg once a day (GA160)
Number of subjects: 59
Study 32761372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg twice a day (G2A100)
Number of subjects: 59
Study 35986416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored health insurance education intervention with a patient navigator that includes usual care
Number of subjects: 80
Study 35986416 — intervention group
Group type: COMPARATOR
Intervention: Usual navigation care
Number of subjects: 80
Study 34479617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic-foot-muscle exercise combined with lower extremity resistance training
Number of subjects: 120
Study 34479617 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic-foot-muscle exercise combined with lower extremity resistance training
Number of subjects: 120
Study 34479617 — intervention group
Group type: COMPARATOR
Intervention: Lower extremity resistance training
Number of subjects: 120
Study 32984232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive aging simulation suit and medication review polypharmacy workshop
Number of subjects: 120
Study 32984232 — intervention group
Group type: COMPARATOR
Intervention: Medication review polypharmacy workshop (control)
Number of subjects: 120
Study 32345116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 133
Study 32345116 — intervention group
Group type: COMPARATOR
Intervention: Naked eye
Number of subjects: 133
Study 32646482 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol and folic acid (4000 mg myo-inositol and 400 mcg folic acid daily)
Number of subjects: 160
Study 32646482 — intervention group
Group type: COMPARATOR
Intervention: folic acid alone (400 mcg folic acid daily)
Number of subjects: 160
Study 33640311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive sirolimus-eluting stent (COMBO)
Number of subjects: 60
Study 33640311 — intervention group
Group type: COMPARATOR
Intervention: Polymer-free biolimus-eluting stent (BioFreedom)
Number of subjects: 60
Study 33279373 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment (MT)
Number of subjects: 103
Study 33279373 — intervention group
Group type: COMPARATOR
Intervention: Dose-reduction/discontinuation (DR)
Number of subjects: 103
Study 33279373 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (not specified)
Number of subjects: 103
Study 35439878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lollipops containing xylitol and erythritol
Number of subjects: 50
Study 35439878 — intervention group
Group type: COMPARATOR
Intervention: Control group (without lollipops)
Number of subjects: 50
Study 33446240 — intervention group
Group type: EXPERIMENTAL
Intervention: Proband, duo, or trio whole‐genome sequencing and proband targeted gene panels
Number of subjects: 1130
Study 33446240 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform (GUÍA) for returning genomic results
Number of subjects: 1130
Study 33446240 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys at baseline (0 months), result disclosure visit (+3 months), and follow‐up visit (+9 months)
Number of subjects: 1130
Study 33446240 — intervention group
Group type: EXPERIMENTAL
Intervention: GenomeDiver digital tool
Number of subjects: 1130
Study 32450344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (25 μg/Kg as bolus infusion, followed by 0.15 μg/Kg/min continuous infusion for 48 hours), acetylsalicylic acid (250 mg infusion and 75 mg daily for 30 days), clopidogrel (300 mg oral and 75 mg daily for 30 days), fondaparinux (2.5 mg/day subcutaneous for duration of hospital stay)
Number of subjects: 5
Study 32450344 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving prophylactic or therapeutic dose heparin
Number of subjects: 5
Study 36288582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior (AP) view
Number of subjects: 204
Study 36288582 — intervention group
Group type: COMPARATOR
Intervention: Oblique (OB) view
Number of subjects: 204
Study 33668679 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine autofluorescence at 295 nm in patients with malignant melanoma
Number of subjects: 0
Study 35042187 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 22
Study 35042187 — intervention group
Group type: COMPARATOR
Intervention: Leucine-Matched Collagen Peptides (CP)
Number of subjects: 22
Study 35042187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WP and CP
Number of subjects: 22
Study 34737469 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and sanitation infrastructure and hygiene promotion intervention
Number of subjects: 40
Study 34737469 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 40
Study 32398324 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily and durvalumab 1,500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Number of subjects: 35
Study 35669374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent delivery room management system
Number of subjects: 100
Study 35669374 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 100
Study 34325550 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive web application (PWA) education
Number of subjects: 52
Study 34325550 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions with demonstration
Number of subjects: 52
Study 33040584 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsened symptom classification (increased Rutherford classification)
Number of subjects: 12759
Study 33040584 — intervention group
Group type: COMPARATOR
Intervention: No change in symptom classification (stable Rutherford classification)
Number of subjects: 12759
Study 33040584 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved symptom classification (decreased Rutherford classification)
Number of subjects: 12759
Study 36435798 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 180
Study 36435798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 33302143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose DPI
Number of subjects: 318
Study 33302143 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 318
Study 33302143 — intervention group
Group type: EXPERIMENTAL
Intervention: No knowledge about COPD
Number of subjects: 318
Study 33302143 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler effectiveness perceived as fair/poor
Number of subjects: 318
Study 33302143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate/poor adherence
Number of subjects: 318
Study 33059419 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (corneal diameter ≤ 11.1 mm)
Number of subjects: 6744
Study 33059419 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (corneal diameter 11.2 to 11.8 mm)
Number of subjects: 6744
Study 33059419 — intervention group
Group type: COMPARATOR
Intervention: Group C (corneal diameter ≥ 11.9 mm)
Number of subjects: 6744
Study 35262715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed (MPS)
Number of subjects: 1501
Study 35262715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed plus bevacizumab (MAPS)
Number of subjects: 1501
Study 35262715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (CM743)
Number of subjects: 1501
Study 35189734 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 1